Nexavar HCC Pricing Analysis Part II
I thought this Nexavar and Sutent prescription sales data was worth revisiting in slightly more detail, given our interest in commercial pharma pricing strategy.
The short video revenue analysis examines global sales of Onyx/Bayer’s Nexavar and Pfizer’s Sutent since the drugs were approved for the treatment of renal cell carcinoma (RCC), and hepateceullular carcinoma (HCC) subsequently, in the case of Nexavar.
The immediate implications on global revenue following the FDA approval for HCC are the particular focus of this brief pricing analysis video. The referenced pharma pricing report will be available soon. Sign up on the right to get these pharma valuable market access insights, first!!
Our next life sciences pricing strategy video will look at the direct implications of epidemiology across various global pharma markets. A particular focus will be the practical realities and limitations of pharma market access and reimbursement growth in the near-term in emerging Asian markets.